Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Selma Ugurel

Showing results (151-160 of 265) with videos related to

Pageof 27
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunityRalf Gutzmer, Anika Koop, Friedegund Meier, et al.
Scientific Reports|September 1, 2025
Distinct liver sections exhibit sex-specific gene expression patterns in Lewis ratsLuisa Sophie Rajcsanyi, Simge Oral, Julia Borgardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100BAnnette Paschen, Antje Sucker, Bettina Hill, et al.
Pigment Cell Research|July 11, 2006
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signatureKeith S Hoek, Natalie C Schlegel, Patricia Brafford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2013
Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-upSelma Ugurel, Thomas Mentzel, Jochen Utikal, et al.
Oncotarget|April 6, 2017
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutationsIoana Cosgarea, Selma Ugurel, Antje Sucker, et al.
Cancer Research|August 4, 2004
Immunogenicity of constitutively active V599EBRafMads Hald Andersen, Joachim Fensterle, Selma Ugurel, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2021
Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer: A retrospective analysis of 47 casesCindy Franklin, Axel Wetter, Hideo Andreas Baba, et al.
Cancer Immunology, Immunotherapy : CII|December 1, 2017
Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMECJürgen C Becker, Andreas Stang, Axel Zur Hausen, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2017
PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanomaKatrin Schaper-Gerhardt, Steven Okoye, Rudolf Herbst, et al.
Pageof 27

Showing results (151-160 of 265) with videos related to

Sort By:
Pageof 27
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunityRalf Gutzmer, Anika Koop, Friedegund Meier, et al.
Scientific Reports|September 1, 2025
Distinct liver sections exhibit sex-specific gene expression patterns in Lewis ratsLuisa Sophie Rajcsanyi, Simge Oral, Julia Borgardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100BAnnette Paschen, Antje Sucker, Bettina Hill, et al.
Pigment Cell Research|July 11, 2006
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signatureKeith S Hoek, Natalie C Schlegel, Patricia Brafford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2013
Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-upSelma Ugurel, Thomas Mentzel, Jochen Utikal, et al.
Oncotarget|April 6, 2017
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutationsIoana Cosgarea, Selma Ugurel, Antje Sucker, et al.
Cancer Research|August 4, 2004
Immunogenicity of constitutively active V599EBRafMads Hald Andersen, Joachim Fensterle, Selma Ugurel, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2021
Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer: A retrospective analysis of 47 casesCindy Franklin, Axel Wetter, Hideo Andreas Baba, et al.
Cancer Immunology, Immunotherapy : CII|December 1, 2017
Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMECJürgen C Becker, Andreas Stang, Axel Zur Hausen, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2017
PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanomaKatrin Schaper-Gerhardt, Steven Okoye, Rudolf Herbst, et al.
Pageof 27